Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Virus Pandemics and Vaccinations
share announcement

Virus Pandemics and Vaccinations

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".

Deadline for manuscript submissions: 1 September 2025 | Viewed by 1129

Special Issue Editors

Dr. Renata Gili

E-Mail
Guest Editor
Department of Prevention, Turin Local Health Authority, 10125 Torino, Italy
Interests: public health; vaccines; prevention; infectious diseases; vaccine hesitancy
Dr. Davide Gori

E-Mail Website
Guest Editor
Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy
Interests: public health; vaccines; prevention; infectious diseases; one health; vaccine hesitancy
Special Issues, Collections and Topics in MDPI journals
Dr. Matteo Riccò

E-Mail
Guest Editor
Local Health Unit of Reggio Emilia, 42122 Reggio Emilia, Italy
Interests: public health; vaccines; prevention; infectious diseases; prevention and protection at work; mass gathering and public health risks
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

While the COVID-19 pandemic is far from being really over, new health threats are continuously emerging, particularly from the interface between human beings, animals, insects, and the ever-changing environmental landscape of the post-globalization world. In such a setting, not only new and effective vaccine strategies targeting both “ancient” (e.g., pox, measles, and influenza) and invasive pathogens (e.g., zika and dengue) are required, but also new vaccination strategies focusing on humans and animals, from the perspective of the One Health approach. Moreover, in such a context, vaccine hesitancy threatens achieving adequate vaccination coverage worldwide.

The present SI will, therefore, welcome observational and interventional studies, along with systematic reviews and meta-analyses, addressing the topics of vaccines, vaccination strategies, emerging pathogens, infection control, and vaccine hesitancy.

Dr. Renata Gili
Dr. Davide Gori
Dr. Matteo Riccò
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • vaccination strategy
  • one health
  • emerging pathogens
  • vaccine hesitancy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 955 KiB  
Article
The Effectiveness of COVID-19 Vaccines During the Pre-Omicron and Omicron Periods: A Retrospective Test-Negative Case–Control Study
by Romeo Brambilla, Renata Gili, Federica Vigna Taglianti, Jacopo Lenzi, Matteo Riccò, Roberto Burioni, Mariaelisabetta Scarvaglieri, Rachele Rocco, Vittorina Buttafuoco, Rosa Maria Teresa Antonia Cristaudo and Davide Gori
Vaccines 2024, 12(11), 1245; https://doi.org/10.3390/vaccines12111245 - 31 Oct 2024
Viewed by 781
Abstract
Background: The aim of this study was to estimate the effectiveness of original and bivalent COVID-19 vaccines in reducing COVID-19-associated hospitalizations among the adult population of Turin, Italy. Methods: We conducted a retrospective, test-negative, case–control study of 5768 adults aged ≥50 years who [...] Read more.
Background: The aim of this study was to estimate the effectiveness of original and bivalent COVID-19 vaccines in reducing COVID-19-associated hospitalizations among the adult population of Turin, Italy. Methods: We conducted a retrospective, test-negative, case–control study of 5768 adults aged ≥50 years who had symptoms that were consistent with COVID-19-like illness and were admitted to the hospitals of the Turin Health Unit network from 1 January 2021 to 31 January 2023. We evaluated the effectiveness of the vaccines that at the time of the study were authorized in the European Union (original/bivalent BNT162b2; original mRNA-1273; ChAdOx1-S; Ad26.COV2.S) by comparing the odds of a positive test for SARS-CoV-2 in vaccinated patients with the odds of a positive test in unvaccinated patients. The association between vaccination status, hospitalization, ICU admission and positive SARS-CoV-2 test was estimated by building multivariate adjusted logistic regression models. Results: During the predominance of the pre-Omicron variants, the vaccine effectiveness of two and three doses received in the last 120 days against COVID-19-associated hospitalizations was 93.6% (95% CI: 90.1 to 95.9) and 97.1% (95% CI: 90.8 to 99.1), respectively. During the predominance of the Omicron variant, the vaccine effectiveness of two and three doses was 26.6% (95% CI: −0.6 to 46.5) and 75.2% (95% CI: 68.1 to 80.7), respectively, and it rose to 88% (95% CI: 78.2 to 93.3) for four or five doses of the bivalent vaccine. Conclusions: Our study confirms that the COVID-19 vaccines protect adult patients from hospitalizations, including the subgroup ≥80 years, also during the period of the Omicron variant’s predominance. Full article
(This article belongs to the Special Issue Virus Pandemics and Vaccinations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop